Kos Biotechnology Partners announced it has closed a financing round in Epikast, a technology-enabled provider of commercial and clinical services for the biopharmaceutical industry. The transaction marks the inaugural investment from Kos’ first fund, which the firm said will target a wide range of life sciences stages, from seeding new platforms to scaling established ones.
Kos said it led the round with significant participation from a syndicate of new and existing investors. As part of the financing, Alex Tzoukas, managing partner and co-founder of Kos, will join Epikast’s board of directors.
Epikast said the new capital will support enhancements to its proprietary technology platform and help scale its specialized service teams. The company positions itself as a bridge between high-level medical expertise and cost-efficient operations, leveraging a Greece-based operational hub to serve global biopharmaceutical clients.
Epikast is headquartered in New York with core operations in Athens, Greece. The company provides remote commercial, medical, market access, and patient support services and said it combines highly trained medical professionals with a proprietary technology stack to deliver engagement and data-driven insights at an optimized cost structure. Epikast said it currently works with several global top 10 pharmaceutical companies as well as smaller biotechnology companies commercializing products in the U.S. and Europe.
Kos, founded in 2025 by Dr. Simos Simeonidis and Alex Tzoukas, said its approach centers on partnering with experienced management teams to build enduring products, services, and platforms through strategic capital, operational expertise, and a long-term value creation perspective.
KEY QUOTES
“Epikast represents an exciting investment for our new fund. The company has developed a differentiated, tech-enabled pharma services model that addresses a clear inefficiency in how biopharma companies engage with healthcare providers and patients. We are pleased to lead this round and support the company as it scales.”
Alex Tzoukas, Managing Partner and Co-Founder, Kos Biotechnology Partners
“We are pleased to welcome Kos Biotechnology Partners as lead investor in this round. Kos brings deep sector expertise and a strong connection to both the US and Greek innovation ecosystems, which aligns well with Epikast’s operating model. Alex’s addition to the board adds valuable perspective as we enter the next phase of growth.”
Dr. Stelios Papadopoulos, Chairman, Epikast
“We are pleased to partner with Stelios and his team at Epikast with the first investment from our fund. Alex’s deep background as a life sciences investor, investment banker, and operator will further enhance the strong expertise already present on Epikast’s Board.”
Dr. Simos Simeonidis, Managing Partner and Co-Founder, Kos Biotechnology Partners
“This financing reinforces Epikast’s strong momentum. We place a premium on partnering with individuals who bring deep expertise and strong judgment. Alex Tzoukas, Simos Simeonidis, and Nikos Kostaras exemplify that and will be valuable partners as we advance our next phase.”
Dr. Vangelis Vergetis, CEO, Epikast
